CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
Gerard Walls, Jamie B. Oughton, Anthony J. Chalmers, Sarah Brown, Fiona Collinson, Martin Förster, Kevin N. Franks, Alexandra Gilbert, Gerard G. Hanna, Nicola Hannaway, Stephen Harrow, Tom Haswell, Crispin T. Hiley, Samantha Hinsley, Matthew Krebs, Geraldine Murden, Rachel Phillip, Anderson J. Ryan, Ahmed Salem, David Sebag‐Montefiore, Paul Shaw, Chris Twelves, Katrina Walker, Robin Young, Corinne Faivre‐Finn, Alastair Greystoke
Abstract
Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.